Skip to main content
Perseus Proteomics Inc. logo

Perseus Proteomics Inc. — Investor Relations & Filings

Ticker · 4882 ISIN · JP3836800007 T Professional, scientific and technical activities
Open in API
Filings indexed 56 across all filing types
Latest filing 2025-06-27 Governance Information
Country JP Japan
Listing T 4882

About Perseus Proteomics Inc.

https://www.ppmx.com/en/

Perseus Proteomics Inc. is a drug discovery biotechnology company specializing in the development of novel antibody-based therapeutics and diagnostics. Originating from the University of Tokyo, the company leverages proprietary antibody technologies and screening platforms to create a pipeline of drug candidates targeting cancer and other diseases. Its business is structured into three main segments: Drug Discovery, which focuses on its internal pipeline; Antibody Research Support, offering services to the research community; and Antibody/Reagent Sales, which provides products like ELISA kits. The company aims to contribute to global healthcare through its advanced antibody-based solutions.

Recent filings

Filing Released Lang Actions
内部統制報告書－第25期(2024/04/01－2025/03/31)
Governance Information Classification · 100% confidence The document is explicitly titled "内部統制報告書" (Internal Control Report) in the header and within the table structure. It references the legal basis as "金融商品取引法第24条の４の４第１項" (Financial Instruments and Exchange Act Article 24-4-4, Paragraph 1), which mandates the filing of an Internal Control Report by listed companies in Japan. The content discusses the framework, scope, criteria (based on the standard issued by the Financial Accounting Standards Board of Japan), and the conclusion that internal controls over financial reporting are effective as of the fiscal year-end (March 31, 2025). This directly corresponds to the definition of an Audit Report / Information (AR), which covers internal or regulatory stress tests and applied accounting principles, although this specific filing is focused purely on internal controls over financial reporting, which fits best under the AR category among the provided options, as it is a formal report on internal processes related to financial reporting, distinct from the full Annual Report (10-K) or a simple Earnings Release (ER).
2025-06-27 Japanese
確認書
Audit Report / Information Classification · 98% confidence The document text contains the header "有価証券報告書（通常方式）" which translates to "Securities Report (Normal Method)". It also explicitly mentions "第25期（自 2024年４月１日 至 2025年３月31日）の有価証券報告書" (Securities Report for the 25th period). Furthermore, the filing details reference the Financial Instruments and Exchange Act ("金融商品取引法") and the submission to the Kanto Local Finance Bureau ("関東財務局長"). A comprehensive Securities Report covering a full fiscal year (April 1, 2024, to March 31, 2025) is the definition of a 10-K filing in the US context, which is the closest equivalent for a full annual statutory report in this classification scheme. Although the document itself appears to be a confirmation statement regarding the accuracy of the report, the core subject matter and context point directly to the Annual Report (10-K). Given the explicit mention of the full annual report and its statutory basis, 10-K is the most appropriate classification, rather than RPA or RNS, as this is the substance of the filing, not just an announcement of it. FY 2025
2025-06-27 Japanese
有価証券報告書－第25期(2024/04/01－2025/03/31)
Annual Report Classification · 100% confidence The document is a 'Yuka Shoken Hokokusho' (Annual Securities Report) filed with the Kanto Local Finance Bureau in Japan. It covers the fiscal year from April 1, 2024, to March 31, 2025. This is the primary annual financial disclosure document for a Japanese public company, equivalent to a 10-K in the US market. It contains detailed financial statements, business descriptions, and management information. FY 2025
2025-06-27 Japanese
臨時報告書
Regulatory Filings Classification · 100% confidence The document is titled "臨時報告書" (Extraordinary Report) and is filed with the Kanto Local Finance Bureau. The content explicitly discusses the resolution to change the company's statutory auditor (会計監査人), detailing the resignation of the current auditor (有限責任あずさ監査法人) and the appointment of a new one (史彩監査法人) to be approved at the upcoming Annual General Meeting (第25回定時株主総会). This type of filing, which reports significant corporate governance or statutory changes outside of routine periodic reports (like 10-K or IR), often falls under general regulatory filings in Japanese contexts. Given the specific nature of reporting auditor changes, it is a significant event disclosure. Since there is no specific code for 'Auditor Change Report,' and it is a formal regulatory disclosure, it best fits the general 'Regulatory Filings' (RNS) category, as it is not an Earnings Release (ER), Audit Report (AR), or Governance Report (CGR) itself, but rather a notification of a procedural change. However, upon reviewing the definitions, the document is a formal disclosure of a significant corporate event (change of auditor) required by financial regulations (金融商品取引法). While RNS is a fallback, the content is highly specific. Since it is not a standard periodic report (10-K, IR) or a specific announcement like DIRS or DIV, RNS remains the most appropriate general regulatory disclosure category for this type of mandatory, non-periodic filing in the provided list.
2025-05-21 Japanese
確認書
Report Publication Announcement Classification · 100% confidence The document text contains the title "第２四半期報告書" (Second Quarter Report) and explicitly mentions the reporting period ("第25期中（自 2024年４月１日 至 2024年９月30日）"). It is a formal confirmation document submitted to the Kanto Local Finance Bureau, referencing Article 24-5-2, Paragraph 1 of the Financial Instruments and Exchange Act. This structure strongly indicates a formal periodic financial report covering a period shorter than a year (a half-year report). This aligns perfectly with the definition of an Interim / Quarterly Report (Code: IR). The document length is very short (583 chars), but the content is the substance of the required confirmation for the report itself, not just an announcement of its publication, making IR more appropriate than RPA/RNS.
2024-11-14 Japanese
半期報告書－第25期(2024/04/01－2025/03/31)
Interim / Quarterly Report Classification · 100% confidence The document is a '半期報告書' (Semi-annual Report) for Perseus Proteomics Inc., covering the period from April 1, 2024, to September 30, 2024. It contains detailed financial statements, management analysis, and audit review information, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2025
2024-11-14 Japanese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.